SACHA Supporters & partners

With the support of:

In France, the National Agency for Drug Safety (ANSM) shares quarterly to the SACHA team data on compassionate prescriptions for approved anticancer treatments for patients under 18 years of age. Between 2020 and 2024, the share of these prescriptions captured in SACHA increased by more than 40%.
As part of the interactions with the ANSM, SACHA was recommended as a data source registry within the framework of the therapeutic use and patient monitoring protocol (PUT-SP) of OJEMDA® (tovorafenib) in low grade glioma (LGG), for which compassionate access authorization is in progress.
SACHA is also the data source recommended by the ANSM to validate the compassionate prescription framework established by means of the therapeutic use and patient monitoring protocol for Qarziba (dinutuximab beta) associated with chemotherapy in the treatment of patients with neuroblastoma.

SACHA is recognized by the French National Authority for Health (HAS) as real-life data sources that can be mobilized to meet its requirements for additional data.
As part of the post-marketing data collection, the HAS recommended SACHA for patients ≤ 25 years old treated with larotrectinib for advanced solid tumors with NTRK fusion, outside of a clinical trial. The SACHAxLaro cohort is implemented as part of the collaboration between Gustave Roussy and Bayer France.